SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
出版年份 2022 全文链接
标题
SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
作者
关键词
metabolic dysfunction-associated fatty liver disease, sodium–glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, insulin resistance
出版物
TRENDS IN ENDOCRINOLOGY AND METABOLISM
Volume 33, Issue 6, Pages 424-442
出版商
Elsevier BV
发表日期
2022-04-29
DOI
10.1016/j.tem.2022.03.005
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- Empagliflozin Improves Liver Steatosis and Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- (2021) Haleh Chehrehgosha et al. Diabetes Therapy
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
- (2021) Lone B Enebo et al. LANCET
- Links between metabolic syndrome and metabolic dysfunction-associated fatty liver disease
- (2021) Soo Lim et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Comparative efficacy of glucose‐lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta‐analysis
- (2021) Apostolos Tsapas et al. DIABETES OBESITY & METABOLISM
- Emerging therapeutic approaches for the treatment of NAFLD and type 2 diabetes mellitus
- (2021) Daniel Ferguson et al. Nature Reviews Endocrinology
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial
- (2021) Juan P Frías et al. Lancet Diabetes & Endocrinology
- Evidence Against an Important Role of Plasma Insulin and Glucagon Concentrations in the Increase in EGP Caused by SGLT2 Inhibitors
- (2020) Mariam Alatrach et al. DIABETES
- Efficacy of exenatide and insulin glargine on nonalcoholic fatty liver disease in patients with type 2 diabetes
- (2020) Lin Liu et al. DIABETES-METABOLISM RESEARCH AND REVIEWS
- MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease
- (2020) Mohammed Eslam et al. GASTROENTEROLOGY
- Short-term GLP-1 receptor agonist exenatide ameliorates intramyocellular lipid deposition without weight loss in ob/ob mice
- (2020) Fen Xu et al. INTERNATIONAL JOURNAL OF OBESITY
- Ipragliflozin Additively Ameliorates Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Controlled with Metformin and Pioglitazone: A 24-Week Randomized Controlled Trial
- (2020) Eugene Han et al. Journal of Clinical Medicine
- Autophagy-dependent and -independent modulation of oxidative and organellar stress in the diabetic heart by glucose-lowering drugs
- (2020) Milton Packer Cardiovascular Diabetology
- A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement
- (2020) Mohammed Eslam et al. JOURNAL OF HEPATOLOGY
- Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders
- (2020) Judith Aron-Wisnewsky et al. Nature Reviews Gastroenterology & Hepatology
- SGLT2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease
- (2020) So Ra Kim et al. Nature Communications
- Evolving role for pharmacotherapy in NAFLD/NASH
- (2020) Suzanna L. Attia et al. CTS-Clinical and Translational Science
- Glucagon‐like peptide‐1 receptor agonists and sodium‐glucose co‐transporter‐2 inhibitors as combination therapy for type 2 diabetes: A systematic review and meta‐analysis
- (2020) Chrysanthi Mantsiou et al. DIABETES OBESITY & METABOLISM
- SGLT-2 Inhibition and the Endocrine Pancreatic Alpha Cell: Direct or Indirect Mechanisms of Inhibition?
- (2020) Juris J Meier et al. ENDOCRINOLOGY
- From NAFLD to MAFLD: Implications of a premature change in terminology
- (2020) Zobair M Younossi et al. HEPATOLOGY
- The GLP-1R agonist liraglutide limits hepatic lipotoxicity and inflammatory response in mice fed a methionine-choline deficient diet
- (2020) Emmanuel Somm et al. Translational Research
- Effect of Empagliflozin on Liver Steatosis and Fibrosis in Patients With Non-Alcoholic Fatty Liver Disease Without Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial
- (2020) Hoda Taheri et al. ADVANCES IN THERAPY
- Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial)
- (2020) Mohammad S. Kuchay et al. DIABETOLOGIA
- SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology
- (2020) Norio Akuta et al. INTERNAL MEDICINE
- MAFLD identifies patients with significant hepatic fibrosis better than NAFLD
- (2020) Sakura Yamamura et al. LIVER INTERNATIONAL
- Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure
- (2020) Milton Packer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Current perspectives on the pathophysiology of metabolic associated fatty liver disease: are macrophages a viable target for therapy?
- (2020) Mikkel Breinholt Kjær et al. Expert Review of Gastroenterology & Hepatology
- GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art
- (2020) Michael A. Nauck et al. Molecular Metabolism
- MAFLD vs. NAFLD: shared features and potential changes in epidemiology, pathophysiology, diagnosis, and pharmacotherapy
- (2020) Ying-Xin Xian et al. CHINESE MEDICAL JOURNAL
- Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial
- (2020) Wen Guo et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Revisiting the Complexity of GLP-1 Action from Sites of Synthesis to Receptor Activation
- (2020) Brent A McLean et al. ENDOCRINE REVIEWS
- Clinical utility of the MAFLD definition
- (2020) Kenneth I. Zheng et al. JOURNAL OF HEPATOLOGY
- Non-alcoholic fatty liver disease: Not time for an obituary just yet!
- (2020) Shivaram Prasad Singh et al. JOURNAL OF HEPATOLOGY
- Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
- (2020) David C Wheeler et al. Lancet Diabetes & Endocrinology
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mitochondrial Dysfunction in Type 2 Diabetes Mellitus: An Organ-Based Analysis
- (2019) Mark V Pinti et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Randomized trial comparing effects of weight loss by liraglutide with lifestyle modification in non‐alcoholic fatty liver disease
- (2019) Joan Khoo et al. LIVER INTERNATIONAL
- Autophagy in liver diseases: Time for translation?
- (2019) Manon Allaire et al. JOURNAL OF HEPATOLOGY
- Accuracy of FibroScan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
- (2019) Peter J. Eddowes et al. GASTROENTEROLOGY
- Empagliflozin for the Treatment of Nonalcoholic Steatohepatitis in Patients with Type 2 Diabetes Mellitus
- (2019) Lee-Lee Lai et al. DIGESTIVE DISEASES AND SCIENCES
- Exenatide once-weekly improves metabolic parameters, endothelial dysfunction and carotid intima-media thickness in patients with type-2 diabetes: An 8-month prospective study
- (2019) Angelo Maria Patti et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients
- (2019) Aino Latva-Rasku et al. DIABETES CARE
- Comparing the effects of ipragliflozin versus metformin on visceral fat reduction and metabolic dysfunction in Japanese patients with type 2 diabetes treated with sitagliptin: A prospective, multicentre, open‐label, blinded‐endpoint, randomized controlled study (PRIME‐V study)
- (2019) Masaya Koshizaka et al. DIABETES OBESITY & METABOLISM
- Amelioration of muscle wasting by glucagon‐like peptide‐1 receptor agonist in muscle atrophy
- (2019) Yeonhee Hong et al. Journal of Cachexia Sarcopenia and Muscle
- Glucagon Receptor Signaling and Lipid Metabolism
- (2019) Katrine D. Galsgaard et al. Frontiers in Physiology
- Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity
- (2019) Philip Newsome et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Liraglutide treatment reduced interleukin 6 in adults with type 1 diabetes but did not improve established autonomic or polyneuropathy
- (2019) C. Brock et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Impact of exenatide on mitochondrial lipid metabolism in mice with nonalcoholic steatohepatitis
- (2019) Srilaxmi Kalavalapalli et al. JOURNAL OF ENDOCRINOLOGY
- Liraglutide in combination with metformin may improve the atherogenic lipid profile and decrease C-reactive protein level in statin treated obese patients with coronary artery disease and newly diagnosed type 2 diabetes: A randomized trial
- (2019) Christian Anholm et al. ATHEROSCLEROSIS
- Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
- (2019) Sabine Kahl et al. DIABETES CARE
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- The SGLT2 inhibitor dapagliflozin attenuates the activity of ROS-NLRP3 inflammasome axis in steatohepatitis with diabetes mellitus
- (2019) Weiling Leng et al. Annals of Translational Medicine
- Liraglutide improves insulin sensitivity in high fat diet induced diabetic mice through multiple pathways
- (2019) Joseph Yi Zhou et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Metabolic and gut microbiome changes following GLP-1 or dual GLP-1/GLP-2 receptor agonist treatment in diet-induced obese mice
- (2019) Mette Simone Aae Madsen et al. Scientific Reports
- Energy restriction in obese women suggest linear reduction of hepatic fat content and time-dependent metabolic improvements
- (2019) Hans-Erik Johansson et al. Nutrition & Diabetes
- Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes
- (2019) Amalia Gastaldelli et al. DIABETES OBESITY & METABOLISM
- Liraglutide ameliorates non-alcoholic steatohepatitis by inhibiting NLRP3 inflammasome and pyroptosis activation via mitophagy
- (2019) Xinyang Yu et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
- (2019) Golnaz Ranjbar et al. METABOLISM-CLINICAL AND EXPERIMENTAL
- Clinical implications of current cardiovascular outcome trials with sodium glucose cotransporter-2 (SGLT2) inhibitors
- (2018) Soo Lim et al. ATHEROSCLEROSIS
- Effect of Empagliflozin on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial (E-LIFT Trial)
- (2018) Mohammad Shafi Kuchay et al. DIABETES CARE
- Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozin
- (2018) David Polidori et al. DIABETES OBESITY & METABOLISM
- Dulaglutide decreases plasma aminotransferases in people with Type 2 diabetes in a pattern consistent with liver fat reduction: a post hoc analysis of the AWARD programme
- (2018) K. Cusi et al. DIABETIC MEDICINE
- Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
- (2018) Jan W. Eriksson et al. DIABETOLOGIA
- Glucagon-like Peptide-1 Receptor Agonists and Cardiovascular Events: Class Effects versus Individual Patterns
- (2018) Soo Lim et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Exenatide Delays the Progression of Nonalcoholic Fatty Liver Disease in C57BL/6 Mice, Which May Involve Inhibition of the NLRP3 Inflammasome through the Mitophagy Pathway
- (2018) Ning Shao et al. Gastroenterology Research and Practice
- Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) Study
- (2018) Takashi Sasaki et al. Journal of Diabetes Investigation
- Effects of liraglutide, metformin, and gliclazide on body composition in patients with both type 2 diabetes and non-alcoholic fatty liver disease: a randomized trial
- (2018) Wen-Huan Feng et al. Journal of Diabetes Investigation
- Evaluation of the effects of dapagliflozin, an SGLT2 inhibitor, on hepatic steatosis and fibrosis by transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease
- (2018) Masanori Shimizu et al. DIABETES OBESITY & METABOLISM
- Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial)
- (2018) Yoshio Sumida et al. HEPATOLOGY RESEARCH
- Liraglutide modulates gut microbiota and reduces NAFLD in obese mice
- (2018) GV Moreira et al. JOURNAL OF NUTRITIONAL BIOCHEMISTRY
- Hepatocyte-Macrophage Acetoacetate Shuttle Protects against Tissue Fibrosis
- (2018) Patrycja Puchalska et al. Cell Metabolism
- Effect of canagliflozin treatment on hepatic triglyceride content and glucose metabolism in patients with type 2 diabetes
- (2018) Kenneth Cusi et al. DIABETES OBESITY & METABOLISM
- Sodium-glucose cotransporter 2 inhibitors regulate ketone body metabolism via inter-organ crosstalk
- (2018) Jin Hee Kim et al. DIABETES OBESITY & METABOLISM
- Liraglutide, sitagliptin and insulin glargine added to metformin: the effect on body weight and intrahepatic lipid in patients with type 2 diabetes mellitus and NAFLD
- (2018) Jinhua Yan et al. HEPATOLOGY
- Impact of SGLT2 inhibitor to histological features and glucose metabolism of non-alcoholic fatty liver disease complicated by diabetes mellitus
- (2018) Norio Akuta et al. HEPATOLOGY RESEARCH
- Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome
- (2018) Soo Lim et al. Obesity Reviews
- Effects of canagliflozin on body composition and hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease
- (2018) Mitsuko Inoue et al. Journal of Diabetes Investigation
- Ipragliflozin, a sodium glucose co-transporter 2 inhibitor, reduces intrahepatic lipid content and abdominal visceral fat volume in patients with type 2 diabetes
- (2017) Akio Ohta et al. EXPERT OPINION ON PHARMACOTHERAPY
- Liraglutide causes large and rapid epicardial fat reduction
- (2017) Gianluca Iacobellis et al. Obesity
- Effects of Bariatric Surgery on Non-alcoholic Fatty Liver Disease: Magnetic Resonance Imaging Is an Effective, Non-invasive Method to Evaluate Changes in the Liver Fat Fraction
- (2017) Dennis M. Hedderich et al. OBESITY SURGERY
- How bariatric surgery affects liver volume and fat density in NAFLD patients
- (2017) Ran B. Luo et al. SURGICAL ENDOSCOPY AND OTHER INTERVENTIONAL TECHNIQUES
- Soluble Uric Acid Activates the NLRP3 Inflammasome
- (2017) Tarcio Teodoro Braga et al. Scientific Reports
- β-Hydroxybutyrate Deactivates Neutrophil NLRP3 Inflammasome to Relieve Gout Flares
- (2017) Emily L. Goldberg et al. Cell Reports
- Randomized trial comparing the effects of gliclazide, liraglutide, and metformin on diabetes with non-alcoholic fatty liver disease
- (2017) Wenhuan Feng et al. Journal of Diabetes
- SGLT2 Inhibition by Empagliflozin Promotes Fat Utilization and Browning and Attenuates Inflammation and Insulin Resistance by Polarizing M2 Macrophages in Diet-induced Obese Mice
- (2017) Liang Xu et al. EBioMedicine
- Liraglutide improves liver microvascular dysfunction in cirrhosis: Evidence from translational studies
- (2017) Fernanda Cristina de Mesquita et al. Scientific Reports
- The Na+/Glucose Cotransporter Inhibitor Canagliflozin Activates AMPK by Inhibiting Mitochondrial Function and Increasing Cellular AMP Levels
- (2016) Simon A. Hawley et al. DIABETES
- Exenatide decreases liver fat content and epicardial adipose tissue in patients with obesity and type 2 diabetes: a prospective randomized clinical trial using magnetic resonance imaging and spectroscopy
- (2016) A. Dutour et al. DIABETES OBESITY & METABOLISM
- Twelve week liraglutide or sitagliptin does not affect hepatic fat in type 2 diabetes: a randomised placebo-controlled trial
- (2016) Mark M. Smits et al. DIABETOLOGIA
- EASL–EASD–EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
- (2016) et al. DIABETOLOGIA
- Exenatide improves both hepatic and adipose tissue insulin resistance: A dynamic positron emission tomography study
- (2016) Amalia Gastaldelli et al. HEPATOLOGY
- Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes
- (2016) Zobair M. Younossi et al. HEPATOLOGY
- Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus
- (2016) Yuya Seko et al. HEPATOLOGY RESEARCH
- Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin
- (2016) Anna Vanderheiden et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease
- (2016) Anders E. Junker et al. JOURNAL OF HEPATOLOGY
- Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis
- (2016) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
- (2016) Matthew James Armstrong et al. LANCET
- The role of the gut microbiota in NAFLD
- (2016) Christopher Leung et al. Nature Reviews Gastroenterology & Hepatology
- Sirtuins and nonalcoholic fatty liver disease
- (2016) Fatiha Nassir et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes
- (2016) Teruo Jojima et al. Diabetology & Metabolic Syndrome
- Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Increases Circulating Zinc-Α2-Glycoprotein Levels in Patients with Type 2 Diabetes
- (2016) Xin Liao et al. Scientific Reports
- The incretin effect in healthy individuals and those with type 2 diabetes: physiology, pathophysiology, and response to therapeutic interventions
- (2016) Michael A Nauck et al. Lancet Diabetes & Endocrinology
- The Gut Microbiota from Lean and Obese Subjects Contribute Differently to the Fermentation of Arabinogalactan and Inulin
- (2016) Marisol Aguirre et al. PLoS One
- Exendin-4 regulates redox homeostasis in rats fed with high-fat diet
- (2015) Shiwei Niu et al. ACTA BIOCHIMICA ET BIOPHYSICA SINICA
- Effects of Insulin Glargine and Liraglutide Therapy on Liver Fat as Measured by Magnetic Resonance in Patients With Type 2 Diabetes: A Randomized Trial
- (2015) An Tang et al. DIABETES CARE
- Liraglutide treatment causes upregulation of adiponectin and downregulation of resistin in Chinese type 2 diabetes
- (2015) Dongmei Li et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- Nonalcoholic Fatty Liver Disease
- (2015) Mary E. Rinella JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The ketone metabolite β-hydroxybutyrate blocks NLRP3 inflammasome–mediated inflammatory disease
- (2015) Yun-Hee Youm et al. NATURE MEDICINE
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effects of exenatide, insulin, and pioglitazone on liver fat content and body fat distributions in drug-naive subjects with type 2 diabetes
- (2014) Yan Bi et al. ACTA DIABETOLOGICA
- SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria
- (2014) Yukihiro Chino et al. BIOPHARMACEUTICS & DRUG DISPOSITION
- Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
- (2014) Yuichiro Eguchi et al. HEPATOLOGY RESEARCH
- Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and Δ-5-desaturase index in a murine model of non-alcoholic steatohepatitis
- (2014) TAKUMI KAWAGUCHI et al. INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia
- (2014) David G. Cotter et al. JOURNAL OF CLINICAL INVESTIGATION
- Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
- (2014) Ele Ferrannini et al. JOURNAL OF CLINICAL INVESTIGATION
- Controlled attenuation parameter (CAP) for the diagnosis of steatosis: A prospective study of 5323 examinations
- (2014) Victor de Lédinghen et al. JOURNAL OF HEPATOLOGY
- The role of the kidneys in glucose homeostasis in type 2 diabetes: Clinical implications and therapeutic significance through sodium glucose co-transporter 2 inhibitors
- (2014) John P.H. Wilding METABOLISM-CLINICAL AND EXPERIMENTAL
- Nonalcoholic Fatty Liver Disease: Pathogenesis and Therapeutics from a Mitochondria-Centric Perspective
- (2014) Aaron M. Gusdon et al. Oxidative Medicine and Cellular Longevity
- Glucose-Induced Glucagon-Like Peptide 1 Secretion Is Deficient in Patients with Non-Alcoholic Fatty Liver Disease
- (2014) Christine Bernsmeier et al. PLoS One
- Obesity, fatty liver disease and intestinal microbiota
- (2014) Nur Arslan WORLD JOURNAL OF GASTROENTEROLOGY
- Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes
- (2014) Lise L Gluud et al. BMJ Open
- Intraportal GLP-1 stimulates insulin secretion predominantly through the hepatoportal-pancreatic vagal reflex pathways
- (2013) Makoto Nishizawa et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- Hydrogen Sulfide Signaling in the Gastrointestinal Tract
- (2013) David R. Linden ANTIOXIDANTS & REDOX SIGNALING
- Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice
- (2013) Atsuo Tahara et al. EUROPEAN JOURNAL OF PHARMACOLOGY
- Neuroprotective Effects of Liraglutide for Stroke Model of Rats
- (2013) Kenichiro Sato et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Direct effect of GLP-1 infusion on endogenous glucose production in humans
- (2012) M. Seghieri et al. DIABETOLOGIA
- Uric Acid Induces Hepatic Steatosis by Generation of Mitochondrial Oxidative Stress
- (2012) Miguel A. Lanaspa et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Effects of Dapagliflozin on Body Weight, Total Fat Mass, and Regional Adipose Tissue Distribution in Patients with Type 2 Diabetes Mellitus with Inadequate Glycemic Control on Metformin
- (2012) Jan Bolinder et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Reproducibility of hepatic fat fraction measurement by magnetic resonance imaging
- (2012) Arian Mashhood et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Functional interactions between the gut microbiota and host metabolism
- (2012) Valentina Tremaroli et al. NATURE
- Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists
- (2012) Daniel J. Cuthbertson et al. PLoS One
- GLP-1 Receptor Activation Inhibits VLDL Production and Reverses Hepatic Steatosis by Decreasing Hepatic Lipogenesis in High-Fat-Fed APOE*3-Leiden Mice
- (2012) Edwin T. Parlevliet et al. PLoS One
- Suppression of Oxidative Stress by -Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
- (2012) T. Shimazu et al. SCIENCE
- Short-term weight loss and hepatic triglyceride reduction: evidence of a metabolic advantage with dietary carbohydrate restriction
- (2011) Jeffrey D Browning et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort
- (2011) Matthew J. Armstrong et al. JOURNAL OF HEPATOLOGY
- GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy
- (2011) Shvetank Sharma et al. PLoS One
- Glucagon-like peptide-1 reduces hepatic lipogenesis via activation of AMP-activated protein kinase
- (2010) Shani Ben-Shlomo et al. JOURNAL OF HEPATOLOGY
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Hepatocyte-Specific Deletion of SIRT1 Alters Fatty Acid Metabolism and Results in Hepatic Steatosis and Inflammation
- (2009) Aparna Purushotham et al. Cell Metabolism
- The Glucagon-Like Peptide-1 Receptor Regulates Endogenous Glucose Production and Muscle Glucose Uptake Independent of Its Incretin Action
- (2008) Julio E. Ayala et al. ENDOCRINOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More